Peritransplantation Use of Ruxolitinib in Myelofibrosis

Uroosa Ibrahim; Giulia Eva Maria Petrone; John Mascarenhas; Alla Keyzner

doi:10.1016/j.bbmt.2020.08.015

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

Original language	English
Pages (from-to)	2177-2180
Number of pages	4
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	12
DOIs	https://doi.org/10.1016/j.bbmt.2020.08.015
State	Published - Dec 2020

Keywords

Allogeneic transplant
HSCT
Myelofibrosis
Ruxolitinib

Access to Document

10.1016/j.bbmt.2020.08.015

Cite this

@article{42dbd92a1249411d8c4441a98fa5b81d,

title = "Peritransplantation Use of Ruxolitinib in Myelofibrosis",

abstract = "Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.",

keywords = "Allogeneic transplant, HSCT, Myelofibrosis, Ruxolitinib",

author = "Uroosa Ibrahim and Petrone, {Giulia Eva Maria} and John Mascarenhas and Alla Keyzner",

note = "Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = dec,

doi = "10.1016/j.bbmt.2020.08.015",

language = "English",

volume = "26",

pages = "2177--2180",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Peritransplantation Use of Ruxolitinib in Myelofibrosis

AU - Ibrahim, Uroosa

AU - Petrone, Giulia Eva Maria

AU - Mascarenhas, John

AU - Keyzner, Alla

PY - 2020/12

Y1 - 2020/12

N2 - Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

AB - Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

KW - Allogeneic transplant

KW - HSCT

KW - Myelofibrosis

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85090963735&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.08.015

DO - 10.1016/j.bbmt.2020.08.015

M3 - Review article

C2 - 32818555

AN - SCOPUS:85090963735

SN - 1083-8791

VL - 26

SP - 2177

EP - 2180

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 12

ER -

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this